Lucy Scientific Discovery Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lucy Scientific Discovery Inc (LSDI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lucy Scientific Discovery Inc vs Its Competitors
- Profitability: Its -27,050.1% net margin compares with 15.9% for the peer group.
- Peer revenue share: Lucy Scientific Discovery Inc accounted for 0.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LSDI Sales vs. its Competitors, Q2 2023
With a net margin of -27,050.05 %, Lucy Scientific Discovery Inc reported lower profitability than its competitors (15.86 %).
Lucy Scientific Discovery Inc generated 0.00 % of the combined sales of its peer group.
Lucy Scientific Discovery Inc vs. its Competitors, Q2 2023
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lucy Scientific Discovery Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lucy Scientific Discovery Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lucy Scientific Discovery Inc's competitor groups requires a Commercial License.
Lucy Scientific Discovery Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lucy Scientific Discovery Inc | - | - | - | Yes |
| Competitors combined (16) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LSDI Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 2 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 3 | Compass Pathways Plc | 282.9% | Outperformed |
| 4 | Indivior Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Johnson and Johnson | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lucy Scientific Discovery Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Lucy Scientific Discovery Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lucy Scientific Discovery Inc | 9.07 | - |
| Johnson and Johnson | 624,738.80 | 97,929.00 |
| Indivior Pharmaceuticals Inc | 4,428.04 | 1,333.00 |
| Definium Therapeutics Inc | 4,139.61 | - |
| Xenon Pharmaceuticals Inc | 3,787.16 | 13.17 |
| Ataibeckley Inc | 2,651.54 | 4.47 |
| SUBTOTAL | 643,672.81 | 99,598.75 |
Sign in to see all competitors of Lucy Scientific Discovery Inc .
Sources: Lucy Scientific Discovery Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lucy Scientific Discovery Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lucy Scientific Discovery Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Lucy Scientific Discovery Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lucy Scientific Discovery Inc | 9 | - | -513,658 |
| Johnson and Johnson | 624,739 | 695,518 | 149,411 |
| Indivior Pharmaceuticals Inc | 4,428 | 1,333,000 | 356,000 |
| Definium Therapeutics Inc | 4,140 | - | - |
| Xenon Pharmaceuticals Inc | 3,787 | 35,597 | -1,105,932 |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| PEERS TOTAL | 643,664 | 696,076 | 132,867 |
Sign in to see all peers for Lucy Scientific Discovery Inc .
Lucy Scientific Discovery Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Lucy Scientific Discovery Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 1.3x | 4.5x | -3.2x |
| Return on Equity | -336.85 % | industry aggregate | -350.25 % |
| Return on Invested Capital | 15.08 % | -2.89 % (avg) | 17.97 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lucy Scientific Discovery Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 350.3 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (38.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lucy Scientific Discovery Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lucy Scientific Discovery Inc | 0.51 | 1.20 | 0.46 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Indivior Pharmaceuticals Inc | 0.29 | 0.84 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Xenon Pharmaceuticals Inc | 5.87 | 18.75 | - |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
Sign in to see all peers for Lucy Scientific Discovery Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lucy Scientific Discovery Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lucy Scientific Discovery Inc | Q4 2023 | - | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Indivior Pharmaceuticals Inc | Q2 2026 | +13.6 % | +577.8 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| PEERS TOTAL | +7.1 % | -4.0 % |
Sign in to see all peers for Lucy Scientific Discovery Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lucy Scientific Discovery Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lucy Scientific Discovery Inc | Q4 2023 | - | - |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Indivior Pharmaceuticals Inc | Q2 2026 | -3.8 % | -61.1 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | +75.2 % |
| Ataibeckley Inc | Q2 2026 | - | - |
Sign in to see all peers for Lucy Scientific Discovery Inc .
Lucy Scientific Discovery Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lucy Scientific Discovery Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Indivior Pharmaceuticals Inc | 28.21% | 68.79% | - |
| Definium Therapeutics Inc | - | - | - |
| Xenon Pharmaceuticals Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
Sign in to see all peers for Lucy Scientific Discovery Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lucy Scientific Discovery Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lucy Scientific Discovery Inc | - | - |
| Johnson and Johnson | 29.63 | 6.38 |
| Indivior Pharmaceuticals Inc | 12.75 | 3.32 |
| Definium Therapeutics Inc | - | - |
| Xenon Pharmaceuticals Inc | - | 287.54 |
| Ataibeckley Inc | - | 592.79 |
| PEERS AVERAGE | 33.88 | 6.46 |
Sign in to see all peers for Lucy Scientific Discovery Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.